MELI, QRVO and ESPR are among after hour movers
Seeking Alpha · 01/11 23:05
Esperion Therapeutics to Sponsor RFK Racing
Esperion Therapeutics to Sponsor RFK Racing
MT Newswires · 01/11 15:53
H.C. Wainwright Reaffirms Their Buy Rating on Esperion (ESPR)
TipRanks · 01/10 11:15
Esperion (ESPR) Receives a Buy from JMP Securities
TipRanks · 01/10 02:45
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), Esperion (ESPR) and Ovid Therapeutics (OVID)
TipRanks · 01/09 11:50
Esperion sees preliminary Q4 U.S. net product revenue $14.4M-$15.1M
Seeking Alpha · 01/09 08:22
Esperion Sees Q4 Net Product Revenue $14.4M to $15.1M; FY Growth 38% to 40% YoY
Benzinga · 01/09 00:14
CLEAR Outcomes Accepted As Late-Breaking Clinical Trial At ACC.23 Annual Scientific Session & Expo Together With World Congress Of Cardiology
Benzinga · 12/19/2022 21:16
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on December 9, 2022, the Compensation Committee of Esperion’s Board of Directors granted 2 new employees 5,600 restricted stock units (RSUs) under Esperion’s ...
GlobeNewswire · 12/13/2022 23:00
Esperion to Participate in January Investor Meetings
ANN ARBOR, Mich., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that the Company plans to present at the J.P. Morgan 41st Annual Healthcare Conference as well as the LifeSci Partners 12th Annual Corporate Access Event. Both in-p...
GlobeNewswire · 12/13/2022 13:00
Esperion (ESPR) Reports Positive Data From CLEAR Study
Esperion (ESPR) announces positive data from the CLEAR Outcomes study, which further strengthens the clinical evidence supporting the role of bempedoic acid for patients and will boost the growth potential of the drug.
Zacks · 12/08/2022 15:04
Is Esperion Therapeutics (ESPR) Outperforming Other Medical Stocks This Year?
Here is how Esperion Therapeutics (ESPR) and TransMedics (TMDX) have performed compared to their sector so far this year.
Zacks · 12/08/2022 14:40
2 Biotech Stocks Options Traders Love Today
Prometheus Biosciences and Esperion Therapeutics both provided drug updates today
Schaeffer's Investment Research · 12/07/2022 17:16
Esperion Therapeutics Reports Sooner Than Expected Positive Data From Nexletol Trial
Benzinga · 12/07/2022 15:22
Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint
– Demonstrates statistically significant and clinically meaningful results – – Bempedoic acid becomes the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events (MACE-4) primary endpoint – – Presentation...
GlobeNewswire · 12/07/2022 13:05
Esperion Says Trial Assessing Nexletol for Lower Cardiovascular Events Risk Showed 'Statistically Significant Risk Reduction'
Esperion Says Trial Assessing Nexletol for Lower Cardiovascular Events Risk Showed 'Statistically Significant Risk Reduction'
MT Newswires · 12/07/2022 11:03
Why Is Esperion Therapeutics (ESPR) Down 16.7% Since Last Earnings Report?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 12/01/2022 16:31
Esperion Therapeutics, Inc.'s (NASDAQ:ESPR) latest 9.4% decline adds to one-year losses, institutional investors may consider drastic measures
To get a sense of who is truly in control of Esperion Therapeutics, Inc. ( NASDAQ:ESPR ), it is important to understand...
Simply Wall St. · 11/21/2022 11:25
Esperion Therapeutics Promotes Ben Halladay to Chief Financial Officer
Esperion Therapeutics Promotes Ben Halladay to Chief Financial Officer
MT Newswires · 11/17/2022 06:03
Ben Halladay appointed CFO of Esperion
Seekingalpha · 11/16/2022 21:14
Webull provides a variety of real-time ESPR stock news. You can receive the latest news about Esperion Therape through multiple platforms. This information may help you make smarter investment decisions.
About ESPR
Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease (ASCVD), or heterozygous familial hypercholesterolemia (HeFH). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NEXLIZET and NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.